Ovarian Serous Cystadenoma
An ovarian serous cystadenoma is a non-cancerous (benign) tumor that develops in the ovary. These growths are typically characterized by their cystic nature and are generally larger than 1 cm in diameter. While they can cause noticeable symptoms due to their size in the pelvis, they are often discovered incidentally during medical investigations for unrelated issues.
[ไม่มีภาพประกอบ]
Key Facts
- It is a benign, non-cancerous tumor of the ovary.
- Typically exceeds 1 cm in diameter.
- Approximately 20% (one fifth) of cases occur in both ovaries simultaneously.
- It is distinct from serous cystadenomas of the pancreas.
- It does not share genetic traits with serous borderline tumors.
Clinical Presentation and Differentiation
Patients with an ovarian serous cystadenoma often present with signs and symptoms associated with a growth in the pelvic region. Under a microscope, these tumors bear a superficial resemblance to serous carcinoma, the most common form of ovarian cancer. However, medical professionals can virtually always distinguish between the two.
Crucially, these benign tumors do not share the genetic characteristics of indeterminate serous tumors—also known as serous borderline tumors—which have the potential to transform into malignant serous carcinoma.
Relation to Other Organs
It is important to note that ovarian serous cystadenomas are entirely unrelated to serous cystadenomas of the pancreas. Having a tumor of this type in the ovary does not increase the risk of developing one in the pancreas, and vice versa.
Diagnostic Procedures
The diagnosis of an ovarian serous cystadenoma involves a combination of imaging and blood chemistry to determine the size and nature of the mass.
Imaging Techniques
- Ultrasound or Color Doppler: Used as the initial step to assess the size and characteristics of the mass.
- CECT: Contrast-Enhanced Computed Tomography (CECT) may be utilized in some cases for more detailed visualization.
Laboratory Investigations
Blood tests are essential for screening and confirming the diagnosis. The CA-125 level is primarily used for initial screening. To further confirm the diagnosis and rule out other conditions, physicians may test for the following markers:
- CEA (Carcinoembryonic antigen)
- Beta hCG (Human chorionic gonadotropin)
- AFP (Alpha-fetoprotein)
- CA19-9 (Cancer antigen 19-9)
- LDH (Lactate dehydrogenase)
Following these diagnostic steps, routine medical investigations are performed before the patient proceeds to surgery.
Summary of Diagnostic Markers
| Category | Test/Procedure | Purpose |
|---|---|---|
| Imaging | Ultrasound / Color Doppler | Initial assessment of mass size and nature |
| Imaging | CECT | Detailed structural imaging |
| Blood Marker | CA-125 | Primary screening |
| Blood Markers | CEA, beta hCG, AFP, CA19-9, LDH | Confirmation of diagnosis |
Frequently Asked Questions
Is ovarian serous cystadenoma cancerous?
No, it is a non-cancerous (benign) type of ovarian tumor.
Can these tumors occur in both ovaries?
Yes, approximately one fifth of cases occur in both ovaries at the same time.
Is this related to pancreatic cystadenomas?
No, ovarian serous cystadenomas are not related to those found in the pancreas; the presence of one does not increase the risk of the other.
How is it different from serous borderline tumors?
Unlike serous borderline tumors, ovarian serous cystadenomas do not share the genetic traits that allow a tumor to transform into serous carcinoma.
What is the first step in diagnosing this condition?
The initial diagnostic step is typically an ultrasound or color doppler study to determine the nature and size of the pelvic mass.